Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lifecore Biomedical, Inc. \De\ (LFCR) Debt to Equity (2016 - 2025)

Historic Debt to Equity for Lifecore Biomedical, Inc. \De\ (LFCR) over the last 17 years, with Q2 2025 value amounting to $90.72.

  • Lifecore Biomedical, Inc. \De\'s Debt to Equity rose 91037.84% to $90.72 in Q2 2025 from the same period last year, while for May 2025 it was $90.72, marking a year-over-year increase of 91037.84%. This contributed to the annual value of $90.72 for FY2025, which is 91037.84% up from last year.
  • Per Lifecore Biomedical, Inc. \De\'s latest filing, its Debt to Equity stood at $90.72 for Q2 2025, which was up 91037.84% from $51.89 recorded in Q1 2025.
  • Lifecore Biomedical, Inc. \De\'s 5-year Debt to Equity high stood at $90.72 for Q2 2025, and its period low was -$27.0 during Q3 2024.
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s median Debt to Equity value was $1.19 (recorded in 2022), while the average stood at $10.4.
  • Within the past 5 years, the most significant YoY rise in Lifecore Biomedical, Inc. \De\'s Debt to Equity was 459816.71% (2023), while the steepest drop was 189404.74% (2023).
  • Over the past 5 years, Lifecore Biomedical, Inc. \De\'s Debt to Equity (Quarter) stood at $1.07 in 2021, then surged by 30.08% to $1.39 in 2022, then soared by 4598.17% to $65.35 in 2023, then crashed by 88.98% to $7.2 in 2024, then surged by 1159.19% to $90.72 in 2025.
  • Its Debt to Equity was $90.72 in Q2 2025, compared to $51.89 in Q1 2025 and $7.2 in Q4 2024.